3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Myeloid
3
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
21
Leukemia
9
Gastrointestinal Stromal Tumors
4
Philadelphia Chromosome
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid
3
Bone Marrow Diseases
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Myeloproliferative Disorders
2
Hematologic Neoplasms
2
Bronchiolitis Obliterans Syndrome
2
Sarcoma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Hematologic Diseases
1
Interventions
Imatinib Mesylate
5
nilotinib
3
ponatinib
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
ruxolitinib
1
bosutinib
1
Zoledronic Acid
1
Denosumab
1
BID protein, human
1
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Bone Marrow Diseases
×
nilotinib
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts
NCT00471497
2020-11-18
ENESTnd
Novartis
Phase 3
Completed
846 enrolled
33 charts
NCT00519090
2011-11-07
ENEST
Novartis
Phase 3
Terminated
6 enrolled
6 charts